Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A protein with new anticancer activity has been identified

2.

Adding Isatuximab to Standard Backbone Prolongs PFS in Myeloma

3.

Prostate cancer Q&A: Improving detection and reducing overtreatment

4.

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

5.

Use of marijuana and alcohol simultaneously is associated with worse outcomes.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot